Join the Oncology Voice Network. Join for Free
The OVERLOOKED KOL
Advanced Practice Providers Medical Science Liaison Key Opinion Leaders Physician Assistants Nurse Practitioners

The OVERLOOKED KOL


Share This Article


Summary

In this episode, Tom Caravela hosts Leticia Price and Dawn O'Reilly to discuss the critical role of Advanced Practice Providers (APPs) in the medical field. They explore the educational backgrounds and capabilities of APPs, emphasizing their often underutilized potential as Key Opinion Leaders (KOLs). Strategies for effectively identifying and engaging APPs are shared, along with advice for Physician Assistants (PAs) and Nurse Practitioners (NPs) transitioning to Medical Science Liaison (MSL) roles. The conversation highlights the importance of networking, resource utilization, and effective time management. The episode concludes with insights into the value of APPs in medical progress and territory planning.

My guests this week are Medical Science Liaisons, Dawn O'Reilly and Letitia Price, who discuss the benefits of Medical Science Liaisons engaging with Advanced Practice Providers.

Learn more about…

👉 What are APPs
👉 Why should MSLs be calling on APPs
👉 How can an NP or PA transition to industry
👉 Why are NPs and PA’s often overlooked
👉 How can MSLs find success in their territory

Click for Source
Advanced Practice Providers, Medical Science Liaison, Key Opinion Leaders, Physician Assistants, Nurse Practitioners

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Oncology approvals in 2020: a year of firsts in the midst of a pandemic
OVN Avatar Laleh Amiri-Kordestani & Richard Pazdur

Oncology approvals in 2020: a year of firsts in the midst of a pandemic

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Value assessment of oncology drugs using a weighted criterion-based approach
OVN Avatar Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer

Value assessment of oncology drugs using a weighted criterion-based approach

Explore OVN